Get the Stockscreener App
2.37
2.60%
0.06
After Hours:
2.40
0.03
+1.27%
Acumen Pharmaceuticals Inc stock is traded at $2.37, with a volume of 180.80K.
It is up +2.60% in the last 24 hours and down -15.36% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$2.31
Open:
$2.3
24h Volume:
180.80K
Relative Volume:
0.97
Market Cap:
$142.39M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-2.0789
EPS:
-1.14
Net Cash Flow:
$-55.66M
1W Performance:
-1.25%
1M Performance:
-15.36%
6M Performance:
-34.17%
1Y Performance:
+0.42%
1-Day Range:
$2.26
$2.38
1-Week Range:
$2.23
$2.455
52-Week Range:
$2.08
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ABOS | 2.37 | 142.39M | 0 | -64.86M | -55.66M | -1.14 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
HC Wainwright Has Bearish Estimate for ABOS FY2024 Earnings - MarketBeat
Analyzing Ginkgo Bioworks (NYSE:DNA) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 14.2% in October - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Catalent, Inc. (NYSE:CTLT) Shares Sold by Farther Finance Advisors LLC - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Given Buy Rating at HC Wainwright - MarketBeat
Earnings call: Acumen Pharmaceuticals reports on Q3 2024 progress - Investing.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2024 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic - TipRanks
Acumen Pharmaceuticals' Shares Drop on Wider 3Q Loss - MarketWatch
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Acumen Reports $258.9M Cash Runway Despite Widening Q3 Loss; Alzheimer's Trial Advances | ABOS Stock News - StockTitan
Earnings Scheduled For November 12, 2024 - Benzinga
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at Stifel Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharma announces new appointment | Biotechnology | The Pharmaletter - The Pharma Letter
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at UBS Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on Tuesday - MarketBeat
Acumen Pharmaceuticals appoints new regulatory chief - Investing.com
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality - The Manila Times
Acumen Pharma Taps Former Sage Executive to Lead Alzheimer's Drug Development | ABOS Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - WICZ
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference - The Manila Times
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference - StockTitan
Uipath Inc Cl A (PATH-N) QuotePress Release - The Globe and Mail
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Decrease in Short Interest - MarketBeat
National Bank Financial Forecasts TSE:BIP Q3 Earnings - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in October - Defense World
Finance/Insurance: PAUL B. MANNING - Virginia Business Magazine
Acumen reveals Alzheimer's trial screening method By Investing.com - Investing.com Australia
Halozyme to Report Third Quarter 2024 Financial and Operating Results - The Malaysian Reserve
Acumen reveals Alzheimer's trial screening method - Investing.com India
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on - The Bakersfield Californian
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
3 US Penny Stocks With Market Caps Under $500M To Consider - Simply Wall St
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Decreases By 7.7% - MarketBeat
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Millennium Management LLC Has $4.87 Million Position in Exponent, Inc. (NASDAQ:EXPO) - Defense World
Millennium Management LLC Makes New Investment in Super Hi International Holding Ltd. (NASDAQ:HDL) - Defense World
Millennium Management LLC Has $4.88 Million Stock Position in Alamo Group Inc. (NYSE:ALG) - Defense World
Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Central Nervous System (CNS) Biomarkers Market Expected - openPR
8.4% CAGR of Pharmaceutical Cartridges Market to Reach USD 3.5 Billion by 2032, Acumen research and consulting - openPR
Renaissance Technologies LLC Acquires Shares of 338,100 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Acumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06 - MSN
MGO Private Wealth LLC Buys 9,590 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Sei Investments Co. Makes New $2.49 Million Investment in Plains GP Holdings, L.P. (NYSE:PAGP) - Defense World
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 19 '24 |
Sale |
3.48 |
8,933 |
31,048 |
108,867 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 18 '24 |
Sale |
3.71 |
4,242 |
15,717 |
211,445 |
| Siemers Eric | Chief Medical Officer |
Jan 18 '24 |
Sale |
3.71 |
3,124 |
11,604 |
117,576 |
| Barton Russell | Chief Operating Officer |
Jan 18 '24 |
Sale |
3.73 |
2,833 |
10,555 |
96,867 |
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):